Indivior Beats Q3 Estimates With $1.32 EPS, Revenue Up 13% to $356M
INDV sits 42% above its 52-week low of $24.74 on elevated volume (2.1× avg).
Summary
Indivior delivered a clean Q3 beat: adjusted EPS of $1.32 against a $1.12 consensus, and revenue of $356 million versus $329.35 million expected, up 13.4% year over year. Net income came in at $137 million, with reported EPS of $1.12. This follows the 8-K and 10-Q filed earlier today and the August guidance raise to $1.295B–$1.365B, so the quarter confirms the SUBLOCADE-led growth story rather than resetting it. The stock has been weak anyway — down 3.0% this quarter and 3.1% year to date — with attention fixed on the pending all-stock merger of equals with Supernus and the $1 billion special dividend to Indivior holders. Shareholder votes on that deal were set for October 15, 2026.
At the time of this announcement, INDV was trading at $35.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $24.74 to $42.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.